Wüthrich B, Häfner G
Schweiz Med Wochenschr. 1980 Feb 23;110(8):281-90.
The efficacy of hyposensitization treatment of pollen allergy has been proven by a series of double blind studies. The clinical success of specific treatment with semi-depot extracts amounts, according to retrospective studies, to 70% and 90% in hay fever and seasonal asthma. Our results, with a success quota averaging 75% obtained by 821 courses of treatment between 1976 and 1978, are within the range reported by other authors. Only 1-2% of the patients experienced a worsening of the allergic symptoms during immunotherapy. The success quota in connection with organ manifestation varied between 65.7% to 86.5% for asthma (up to 34% cured), 59,8% to 79% for rhinitis and 70,5% to 84% for conjuncitivitis. The global results of 409 hyposensitization treatments by outside practitioners in pollen season 1976 were not inferior statistically to those obtained by our allergy unit. The results after 2 and 3 courses, with a success quota of 85%, were statistically significantly better than after the first course. The local reactions observed in approximately 27% of patients, and the allergic generalized reactions seen in approximately 7% during hyposensitization, are described and discussed. Guidelines for the indication for hyposensitization treatment of pollinosis, for the composition of the pollen extracts (only a few relevant allergens!) and for practical performance are given.
一系列双盲研究已证实花粉过敏的减敏治疗具有疗效。根据回顾性研究，使用半长效提取物进行特异性治疗在花粉症和季节性哮喘中的临床成功率分别为70%和90%。我们的研究结果显示，在1976年至1978年间进行的821个疗程治疗中，平均成功率为75%，与其他作者报告的范围相符。只有1%-2%的患者在免疫治疗期间出现过敏症状加重。与器官表现相关的成功率在哮喘中为65.7%至86.5%（高达34%治愈），鼻炎为59.8%至79%，结膜炎为70.5%至84%。1976年花粉季节外院医生进行的409次减敏治疗的总体结果在统计学上并不逊于我们过敏科的结果。两疗程和三疗程后的结果成功率为85%，在统计学上显著优于第一疗程后的结果。本文描述并讨论了在减敏治疗期间约27%的患者观察到的局部反应以及约7%的患者出现的全身性过敏反应。文中给出了花粉症减敏治疗的适应症、花粉提取物的组成（仅含少数相关变应原！）以及实际操作的指导原则。
